Alto Neuroscience Losses Widen Amid Stable R&D Spend

Ticker: ANRO · Form: 10-Q · Filed: 2025-08-13T00:00:00.000Z

Sentiment: bearish

Topics: Biotechnology, Clinical Trials, Net Loss, Cash Burn, IPO, Pharmaceuticals, Mental Health

Related Tickers: ANRO

TL;DR

**ANRO is burning cash faster than expected, making future financing rounds critical for its long-term survival.**

AI Summary

Alto Neuroscience, Inc. reported a net loss of $17.706 million for the three months ended June 30, 2025, an increase from $16.030 million for the same period in 2024. For the six months ended June 30, 2025, the net loss was $32.875 million, up from $29.447 million in 2024. Research and development expenses remained relatively stable at $13.124 million for the quarter and $23.098 million for the six months in 2025, compared to $13.184 million and $23.136 million respectively in 2024. General and administrative expenses increased to $5.558 million for the quarter and $11.260 million for the six months in 2025, from $5.157 million and $9.591 million in 2024. The company's cash and cash equivalents decreased to $147.585 million as of June 30, 2025, from $168.229 million at December 31, 2024. Alto Neuroscience completed its initial public offering in February 2024, raising net proceeds of $133.0 million, which significantly bolstered its capital resources. The company continues to incur significant operating losses, with an accumulated deficit of approximately $171.3 million as of June 30, 2025, and will require additional capital to fund future operations.

Why It Matters

Alto Neuroscience's widening net losses and declining cash reserves, despite a recent $133.0 million IPO in February 2024, signal a critical need for continued capital raises to fund its clinical-stage pipeline. For investors, this highlights the high-risk, high-reward nature of biopharmaceutical investments, where profitability is distant. Employees face ongoing pressure to deliver clinical trial success to secure the company's future. Customers, specifically patients suffering from MDD, BPD, TRD, and schizophrenia, depend on Alto's ability to advance its seven clinical-stage assets. In a competitive landscape, Alto's 'Precision Psychiatry Platform' must demonstrate superior efficacy to justify its burn rate and attract further investment.

Risk Assessment

Risk Level: high — Alto Neuroscience reported an accumulated deficit of approximately $171.3 million as of June 30, 2025, and a net loss of $32.875 million for the six months ended June 30, 2025. Cash and cash equivalents decreased by $20.644 million in the six months ended June 30, 2025, indicating a significant cash burn rate that necessitates future capital raises.

Analyst Insight

Investors should closely monitor Alto Neuroscience's clinical trial progress and cash burn rate. Given the significant accumulated deficit and ongoing losses, potential investors should exercise caution and consider the high likelihood of future dilutive equity financings.

Financial Highlights

debt To Equity
0.28
revenue
N/A
operating Margin
N/A
total Assets
$157.877M
total Debt
$34.465M
net Income
-$17.706M
eps
-$0.65
gross Margin
N/A
cash Position
$147.585M
revenue Growth
N/A

Key Numbers

Key Players & Entities

FAQ

What were Alto Neuroscience's net losses for the second quarter and first half of 2025?

Alto Neuroscience reported a net loss of $17.706 million for the three months ended June 30, 2025, and a net loss of $32.875 million for the six months ended June 30, 2025.

How did Alto Neuroscience's cash and cash equivalents change from December 2024 to June 2025?

Cash and cash equivalents for Alto Neuroscience decreased from $168.229 million as of December 31, 2024, to $147.585 million as of June 30, 2025.

What is Alto Neuroscience's accumulated deficit as of June 30, 2025?

As of June 30, 2025, Alto Neuroscience had an accumulated deficit of approximately $171.3 million, reflecting significant operating losses since its inception.

When did Alto Neuroscience complete its initial public offering and how much did it raise?

Alto Neuroscience completed its initial public offering in February 2024, issuing 9,246,000 shares at $16.00 per share and receiving net proceeds of $133.0 million.

What are the primary therapeutic areas Alto Neuroscience's pipeline addresses?

Alto Neuroscience's pipeline focuses on high-need therapeutic areas including major depressive disorder (MDD), bipolar depression (BPD), treatment resistant depression (TRD), and schizophrenia.

How have Alto Neuroscience's research and development expenses trended?

Research and development expenses remained relatively stable, at $13.124 million for the three months ended June 30, 2025, compared to $13.184 million for the same period in 2024.

What is the significance of Alto Neuroscience's 'Precision Psychiatry Platform'?

The 'Precision Psychiatry Platform' is Alto Neuroscience's proprietary technology aimed at discovering brain-based biomarkers to identify patients more likely to respond to its novel product candidates, thereby personalizing treatment options.

What is the risk associated with Alto Neuroscience's current financial position?

The company's significant accumulated deficit of $171.3 million and ongoing net losses indicate a high financial risk, as it will need to raise additional capital to fund future operations and achieve profitability.

How many common shares of Alto Neuroscience were outstanding as of August 8, 2025?

As of August 8, 2025, the number of shares of Alto Neuroscience's Common Stock outstanding was 27,076,629.

What is Alto Neuroscience's strategy for achieving profitability?

Alto Neuroscience's transition to profitability depends on the successful development, regulatory approval, and commercialization of its product candidates, along with generating sufficient revenues to support its cost structure.

Risk Factors

Industry Context

Alto Neuroscience operates in the biotechnology sector, focusing on developing treatments for neurological and psychiatric disorders. This industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies in this space often rely heavily on external financing to fund their operations until a product reaches commercialization.

Regulatory Implications

As a biotechnology company, Alto Neuroscience is subject to stringent regulatory oversight from bodies like the FDA. The development and approval process for new therapies is lengthy and costly. Any delays or failures in clinical trials or regulatory submissions could have a material adverse impact on the company's financial condition and prospects.

What Investors Should Do

  1. Monitor cash burn rate and future financing needs closely, given the increasing net losses and decreasing cash reserves.
  2. Evaluate the progress of R&D programs and clinical trials for potential catalysts and future revenue streams.
  3. Assess the impact of rising G&A expenses on overall cost structure and profitability.
  4. Understand the terms and potential dilution associated with the Convertible Grant Agreement and any future capital raises.

Key Dates

Glossary

Accumulated deficit
The cumulative net losses of a company since its inception, minus any cumulative net income. It represents the total loss that has not been offset by profits. (Indicates the company's historical unprofitability and its reliance on external funding to cover past losses.)
Operating right-of-use asset
An asset recognized under lease accounting standards representing the lessee's right to use an underlying asset for the lease term. (Reflects the company's long-term lease commitments for assets like office space or equipment.)
Convertible Grant Agreement
A type of agreement where a grant can be converted into equity under certain conditions, often used in early-stage financing or for specific research collaborations. (Represents a form of financing that may convert to equity, impacting future share count and dilution.)
Weighted-average number of common shares outstanding
The average number of a company's shares that have been outstanding during a reporting period, adjusted for dilutive effects of options and convertible securities. (Used to calculate earnings per share (EPS) and is important for understanding potential dilution.)

Year-Over-Year Comparison

Compared to the prior year, Alto Neuroscience has seen an increase in net losses for both the three-month and six-month periods ending June 30, 2025. While R&D expenses have remained stable, General and Administrative expenses have increased, contributing to the wider net loss. The company's cash position has decreased, and its accumulated deficit has grown, underscoring its continued reliance on external capital. No new significant risks were explicitly detailed in the provided text compared to the previous period, but the existing financial pressures have intensified.

Filing Stats: 4,612 words · 18 min read · ~15 pages · Grade level 19.2 · Accepted 2025-08-13 16:33:00

Key Financial Figures

Filing Documents

- Financial Information

Part I - Financial Information

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) F- 1

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 22

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 37

Controls and Procedures

Item 4. Controls and Procedures 37

- Other Information

Part II - Other Information

Legal Proceedings

Item 1. Legal Proceedings 38

Risk Factors

Item 1A. Risk Factors 38

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 38

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 38

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 39

Other Information

Item 5. Other Information 39

Exhibits

Item 6. Exhibits 40

Signatures

Signatures 42 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical fact contained in this Quarterly Report, including statements regarding our plans, objectives, goals, strategies, future events, future revenues or performance, financing needs, plans, or intentions relating to product candidates and markets and business trends are forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "can," "contemplate," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "objective," "plan," "potential," "predict," "project," "shall," "should," "target," "will," or "would," or the negative of these words or other similar terms or expressions. These statements involve known and unknown risks, uncertainties, and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress, and results of our research and development programs, preclinical studies, any clinical trials, and IND and other regulatory submissions; the ability of our approach to reproducibly predict treatment outcomes for product candidates amongst identified patient populations and achieve clinical success; our ability to continue to identify appropriate biomarkers for use in further clinical development; the timing of and costs involved in obtaining and maintaining regulatory approval of our current

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited). Alto Neuroscience, Inc. and Subsidiary Condensed Consolidated Balance Sheets (Unaudited) (in thousands, except per share amounts) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 147,585 $ 168,229 Prepaid expenses and other current assets 2,261 1,108 Total current assets 149,846 169,337 Restricted cash 500 500 Property and equipment, net 2,308 2,666 Operating right-of-use asset 4,653 5,035 Other assets 570 4 Total assets $ 157,877 $ 177,542 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 1,671 $ 1,579 Accrued expenses and other current liabilities 6,458 8,429 Total current liabilities 8,129 10,008 Term loan, non-current 20,122 10,254 Convertible Grant Agreement 2,000 1,304 Lease liability, long-term 4,214 4,516 Total liabilities 34,465 26,082 Commitments and contingencies (Note 11) Stockholders' equity: Common stock (par value $ 0.0001 ), 500,000 shares authorized; 27,072 and 26,987 shares issued and outstanding as of June 30, 2025 and December 31, 2024 3 3 Additional paid-in capital 294,649 289,954 Accumulated deficit ( 171,271 ) ( 138,396 ) Accumulated other comprehensive income (loss) 31 ( 101 ) Total stockholders' equity 123,412 151,460 Total liabilities and stockholders' equity $ 157,877 $ 177,542 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. F-1 Table of Contents Alto Neuroscience, Inc. and Subsidiary Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except per share amounts) Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 13,124 $ 13,184 $ 23,098 $ 23,136 General and administrative 5,558 5,157 11,260 9,591 Total operating expenses 18,682 18,341 34,358 32,727 Loss from operations ( 18,682 ) ( 18,341 ) ( 34,358 ) ( 32,727

View on Read The Filing